Our results show that the xCT expression is not only a good candidate biomarker for diagnosis of lung cancer but also associated with response to sulfasalazine, suggesting the potential pertinence of xCT expression as a novel candidate companion biomarker in NSCLC. Here, SLC7A11 is linked to lung cancer.